Emergent Disruptions in Theranostics Industry in 2024 – Market Trends and Technology

 

The theranostics market, a fusion of therapy and diagnostics, is undergoing a transformative phase, marked by a surge in acquisitions totaling around $1.5 billion in the last two years. This growth trajectory is propelled by the increasing emphasis on personalized medicine, where diagnostic imaging plays a pivotal role in targeted therapy. With imaging giants like GE, Fuji, and Canon securing 180 patents from the FDA, the next 2-3 years promise a significant evolution for both pharmaceutical manufacturers and imaging leaders.

Analysts at MarketsandMarkets estimates that Theranostics market is projected to escalate from $2.1 billion in 2023 to $4.3 billion by 2028, the market is set to expand at a CAGR of 15.5%. This growth is underpinned by the rising establishment of hospitals, a shift towards targeted therapies, and the introduction of novel theranostic approaches. The integration of artificial intelligence (AI) is enhancing diagnostic accuracy, while recent FDA approvals are boosting the adoption of theranostics.

The drive towards precision medicine is a key market driver, offering tailored treatments based on individual genetic and cellular profiles. This approach not only promises improved outcomes and reduced side effects but also aligns with the theranostic principle of delivering personalized, targeted therapies. However, the market faces challenges, notably the short half-life of radiopharmaceuticals, which necessitates proximity between production and usage sites, increasing investment and operational costs.

Key market players are strategically positioning themselves in these regions, with initiatives like the establishment of centralized radio pharmacies in China by 2025.

Yet, the market is not without its hurdles. The shortage of trained professionals, coupled with budget constraints in healthcare facilities, especially in developing countries, poses a significant challenge. This scenario is exacerbated by the high cost of sophisticated equipment and the reliance on third-party payers for reimbursement, hindering investment in advanced modalities.

While the theranostics market is poised for substantial growth, driven by advancements in precision medicine and AI, it must navigate the challenges of operational costs, regulatory hurdles, and the need for skilled professionals. The strategic expansion into emerging markets, coupled with innovation in theranostic technologies, holds the key to overcoming these obstacles and realizing the full potential of this promising field.

Inquire Now: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=111696976

The key market trends in Theranostics Industry

Radiopharm Theranostics' Strategic Acquisition

Radiopharm Theranostics, a prominent developer in the radiopharmaceutical sector for diagnostic and therapeutic purposes, has made a significant move by acquiring Pharma15 Corporation. This acquisition marks a pivotal step in advancing next-generation therapeutic radiopharmaceuticals specifically targeting prostate cancer. Pharma15, under the leadership of Professor David Ulmert and CEO Suzanne Dance, is at the forefront of developing assets aimed at overcoming resistance to prostate-specific membrane antigen (PSMA) targeting therapies. Their work is notable for its highly specific targeting of cancer cell receptors, minimizing toxicity, and potentially revolutionizing targeted radiotherapy in prostate cancer treatment.

The acquisition agreement includes milestones related to significant clinical developments, such as the submission of an Investigational New Drug Application to the U.S. FDA, highlighting the forward-looking approach of this partnership. The collaboration between Radiopharm and Pharma15, backed by strong academic networks in Europe and the USA, sets a promising trajectory for the clinical advancement of these innovative radiopharmaceuticals.

Innovative Radiopharmaceutical Technologies

Radiopharm Theranostics is pioneering in the field of radiopharmaceuticals with a focus on oncological diseases. Their innovative technology platform, Nano-mAbs, is a testament to their commitment to advancing cancer treatment. Developed by Dr. Hong Hoi Ting, Nano-mAbs utilizes genetically engineered camelid-derived single-domain antibodies (sdAb) labeled with therapeutic radioisotopes. This platform is designed for both therapeutic and diagnostic applications, targeting specific cancer markers such as HER-2, TROP-2, and PD-L1.

Strategic Focus on αvβ6 Integrin for Pancreatic Cancer

The exploration of αvβ6 integrin as a target for pancreatic cancer is a strategic move by Radiopharm. This target is based on the invention of Professor Johannes Notni and is a strong and selective ligand for αvβ6-integrin, a cell surface protein. High levels of αvβ6-integrin are found in several challenging cancers, including pancreatic carcinoma. The αvβ6 integrin offers exceptional performance for radiolabeling with Gallium-68, making it a promising candidate for early detection and treatment of pancreatic cancer and other carcinomas.

Collaboration with Lantheus on NM-01 Theranostic Agent

The collaboration with Lantheus to develop NM-01, a nanobody for theranostic applications, aligns with Radiopharm's innovative approach. NM-01, developed from camelid-derived single-domain antibodies, can be labeled with radioisotopes for both diagnosing and treating tumors. This collaboration signifies Radiopharm's dedication to leveraging its technological advancements for practical therapeutic applications, particularly in the treatment of PD-L1-positive non-small cell lung cancer.

A comprehensive approach to cancer treatment, combining innovative radiopharmaceutical technologies with strategic collaborations is playing out strongly in emergent markets. By focusing on novel targets like αvβ6 integrin and PD-L1, and partnering with industry leaders like Lantheus, Radiopharm is at the forefront of developing next-generation theranostic solutions for oncological diseases.

These developments are on the expected lines of Radiopharm's innovation and the need for strategic vision in addressing unmet needs in cancer treatment, positioning them as a key player in the advancement of radiopharmaceuticals for oncology.

Emerging economies present significant growth opportunities, despite cost concerns. The burgeoning population in countries like India and China, coupled with the high incidence of chronic diseases, offers a sustainable market for theranostics.

Lilly's Strategic Move: Completing the Acquisition of POINT Biopharma for Cancer Therapy Advancement

Eli Lilly and Company (Lilly) has completed the acquisition of POINT Biopharma Global Inc. (POINT), a notable radiopharmaceutical company engaged in the development of radioligand therapies for cancer treatment. This acquisition, announced on December 27, 2023, signifies Lilly's entry into the radioligand therapy space, a move that Jacob Van Naarden, Executive Vice President and President of Loxo@Lilly, believes holds great promise for advancing cancer treatment.

The acquisition was finalized following Lilly's tender offer to purchase all issued and outstanding shares of POINT at $12.50 per share in cash. This offer concluded on December 22, 2023, with approximately 67.97% of POINT's shares being validly tendered. Following this successful tender offer, Lilly proceeded with a second-step merger, resulting in POINT's common stock being delisted from the NASDAQ Capital Market.

Lilly's acquisition of POINT is supported by financial advisory from Goldman Sachs & Co. LLC and legal counsel from Kirkland & Ellis LLP. POINT's financial and legal advisories were provided by Centerview Partners LLC and Skadden, Arps, Slate, Meagher & Flom LLP, respectively.

This strategic acquisition aligns with Lilly's mission to unite caring with discovery to create medicines that improve life for people around the world. Lilly, with a history of nearly 150 years of pioneering life-changing discoveries, continues to focus on addressing significant health challenges, including diabetes care, obesity treatment, Alzheimer's disease, immune system disorders, and cancer.

The acquisition of POINT Biopharma is expected to enhance Lilly's portfolio with next-generation radioligand therapies, potentially improving outcomes for patients with cancer. However, the press release also contains forward-looking statements that involve inherent risks and uncertainties, including those related to drug research, development, and commercialization.

Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=111696976

Pfizer and Seagen: A Historic Milestone in Cancer Treatment Achieved

In December 2023, Pfizer's acquisition of Seagen marked a historic milestone in the ongoing battle against cancer, positioning Pfizer at the forefront of oncological innovation. This strategic union was driven by a shared vision to revolutionize cancer treatment, combining Seagen's expertise in antibody-drug conjugates (ADCs) with Pfizer's extensive capabilities and resources. The collaboration set out to expedite the development and dissemination of groundbreaking radioligand therapies, offering renewed hope to patients globally.

Key Highlights

Historic Acquisition: The acquisition of Seagen by Pfizer, a leader in ADC technology, underscored a significant commitment to advancing the field of cancer care. This partnership promised to transform the treatment landscape for various cancers, aiming to introduce innovative therapies to those in need.

Oncology Investment: Representing one of Pfizer's largest investments to date, the acquisition of Seagen reflected its ongoing pursuit of development and progress in oncology. Pfizer's goal was to harness Seagen's proprietary ADC technology to forge therapies that markedly improve patient outcomes.

Visionary Leadership: Under the guidance of Pfizer's leadership, including Dr. Albert Bourla and Chris Boshoff, the transformative potential of this acquisition was emphasized. The merger of Seagen's scientific prowess with Pfizer's global reach and expertise was envisioned to lead the oncology sector, fulfilling the longstanding promise of more effective cancer treatments.

Expanded Oncology Portfolio: This partnership significantly broadened Pfizer's oncology portfolio with Seagen's advanced ADCs and other pioneering treatments. This diverse array of therapies was set to tackle the complex challenges of cancer care, striving for breakthroughs in treatment efficacy and patient well-being.

The collaboration between Pfizer and Seagen has brought a new chapter in cancer care, driven by the ambition and willingness. We look forward and continue to monitor how these are put to use and have the most daunting cancers brought under manageable conditions. Through this partnership, Pfizer reaffirmed its commitment to enhancing the lives of millions, moving closer to a future where cancer can be effectively treated or even eradicated.

Theranostics advancements in the backdrop of ailments in 2024

In 2024, the theranostics market is witnessing significant advancements in the treatment of prostate cancer, bone metastasis, neuroendocrine tumors, lymphoma, and cardiovascular (CV) diseases. For prostate cancer, theranostics are revolutionizing patient care by enabling precise targeting of cancerous cells with minimal side effects, leveraging radiolabeled ligands that bind to prostate-specific membrane antigen (PSMA). This approach not only improves diagnostic accuracy but also tailors treatment to individual patient profiles, enhancing outcomes.

Bone metastasis treatment is benefiting from theranostics through the use of radiopharmaceuticals that target bone-seeking isotopes, providing both palliative care and valuable diagnostic information. This dual functionality is crucial for managing pain and monitoring disease progression in metastatic cancers.

Neuroendocrine tumors (NETs) are being effectively managed with peptide receptor radionuclide therapy (PRRT), a theranostic approach that combines diagnostic imaging and targeted radionuclide therapy. PRRT allows for the direct targeting of tumor cells expressing specific receptors, significantly improving patient prognosis.

Lymphoma treatment is evolving with the application of antibody-drug conjugates (ADCs) and radiolabeled antibodies, marking a shift towards more personalized and effective treatment strategies. These theranostic tools facilitate the identification and destruction of lymphoma cells with high precision.

In CV diseases, theranostics are emerging as a promising field, particularly in the identification and treatment of atherosclerotic plaques. Radiolabeled molecules that target specific markers of inflammation and plaque formation are under investigation, offering the potential for early detection and targeted therapy of CV conditions.

Evolution of Imaging Analytics and Predictive Modeling Software in 2024

The year 2024 is witnessing a transformative evolution in imaging analytics and predictive modeling software within the theranostics market. These technologies are becoming increasingly sophisticated, integrating artificial intelligence (AI) and machine learning (ML) algorithms to analyze medical images with unprecedented accuracy and speed. This evolution is enabling healthcare providers to detect diseases at earlier stages and predict disease progression with greater precision.

Imaging analytics software is now capable of processing complex imaging data from PET, MRI, and CT scans to identify subtle patterns that may indicate the presence of tumors or metastases. These tools are particularly valuable in oncology, where early detection can significantly impact treatment outcomes. The software's ability to quantify tumor burden and monitor response to therapy over time is enhancing personalized treatment planning and follow-up care.